Nexalin Technology, Inc. Common Stock
$4.89
$0.04 (+0.72%)
$4.80Day Range$4.89
Key Statistics
Market Cap
$4.02M
Shares Outstanding
0.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 16, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$4.89
Day High
$4.89
Day Low
$4.80
Volume
6.9K
VWAP
$4.82
Prev Close
$4.85
Transactions
--
Acc. Volume
--
About Nexalin Technology, Inc. Common Stock
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUSSIC 38458 employees1776 YORKTOWN, HOUSTON, TX, 77056(832) 260-0222IPO Sep 16, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001527352
- Composite FIGI
- BBG014CRDGH9
- Share Class FIGI
- BBG014CRDHD1
- Ticker Root
- NXL
- SIC Code
- 3845
About Nexalin Technology, Inc. Common Stock (NXL) Stock
Nexalin Technology, Inc. Common Stock (NXL) closed the 2026-09-16 session at $4.88, up 0.72% versus the previous close (+0.04). The stock opened at $4.89 and traded between $4.80 and $4.89 during that session. Session trading volume was 7K shares. The volume-weighted average price (VWAP) is $4.82.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Nexalin Technology, Inc. Common Stock has a market capitalization of $4.0 million. The company operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry classification. NXL is listed on the XNAS exchange. The company employs approximately 8 people. Nexalin Technology, Inc. Common Stock is headquartered in HOUSTON, TX. The recorded listing date is 2022-09-16.
On this page you can find market NXL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector.